Gara Jalqabaatti › Kanisa Harkaa › Tennessee › Nashville
Qorannoo klinikaalii Kanisa Harkaa Nashville, TN keessatti
Qorannoo 28 Kanisa Harkaa f Nashville fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Namoota walitti qabaa jiraSadarkaa 2/3
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Namoota walitti qabaa jiraSadarkaa 3
- Sarah Cannon Research Institute (SCRI) - Oncology Partners, Nashville
IKS014 in Advanced Solid Tumors That Express HER2
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Namoota walitti qabaa jiraSadarkaa 1/2
- Vanderbilt University Medical Center, Nashville
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Namoota walitti qabaa jiraSadarkaa 1/2
- Vanderbilt Ingram Cancer Center, Nashville
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institue, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Nashville
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- SCRI Oncology Partners, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- US Oncology Research LLC, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
- Vanderbilt University Medical Center, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Namoota walitti qabaa jiraQorannoo ilaalaa
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Vanderbilt University Medical Center, Nashville
- HCA Midwest Health, Nashville
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Tennessee Oncology, Nashville
Qorannoo Kanisa Harkaa magaalota biroo keessatti
- Houston, TXQorannoo 42
- Boston, MAQorannoo 32
- New York City, NYQorannoo 31
- Baldwin Park, CAQorannoo 22
- Los Angeles, CAQorannoo 22
- Arlington, VAQorannoo 20
- Dallas, TXQorannoo 19
- San Antonio, TXQorannoo 19
- St. Louis, MOQorannoo 18
- Grand Rapids, MIQorannoo 18
- Washington, DCQorannoo 16
- Chicago, ILQorannoo 16
Qorannoo biroo Nashville keessatti
- Kansara Qara'a Non-Small CellQorannoo 97
- Saree OljooQorannoo 81
- Kansara MetastatikiiQorannoo 70
- Kansarii ColorectalQorannoo 69
- Saree (Gosoota Hunda)Qorannoo 65
- Kansarii OvariiQorannoo 49
- Kansarii ProstateQorannoo 43
- Dhibee QaraQorannoo 40
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 39
- Kansarii PancreasQorannoo 39
- Kansa EndometiriyaaliiQorannoo 38
- MelanomaQorannoo 33
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.